4-isobutyl-2-phenylpyrimidine-5-carboxylic acid | 1220450-59-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-isobutyl-2-phenylpyrimidine-5-carboxylic acid
• CAS: 1220450-59-8
• 化学式: C₁₅H₁₆N₂O₂
• 分子量: 256.304
• InChiKey: HIILBDBXIQFVIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.04
• 重原子数：
  19.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  63.08
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  4-isobutyl-2-phenylpyrimidine-5-carboxylic acid 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 反应 2.5h， 生成
  参考文献：
  名称：

  Efficient Assembly of 2,5,6-Substituted Pyrimidines via MgI₂-Mediated Morita−Baylis−Hillman Reaction

  摘要：

  A mild and efficient protocol for the synthesis of a 2,6-disubstituted pyrimidine-5-carboxylate library via a Morita-Baylis-Hillman (MBH) adduct is described. Herein, the three step methodology involves the use of substituted alpha-iodomethylene beta-keto ester intermediates obtained after oxidation of the MBH adducts, which are condensed with various types of amidine or guanidine derivatives, to generate the 2, 6-disubstituted pyrimidines-5-carboxylate libraries.

  DOI：

  10.1021/cc100001e
• 作为产物：
  描述：

  在 potassium hydroxide 作用下， 以 甲醇 为溶剂， 以96%的产率得到4-isobutyl-2-phenylpyrimidine-5-carboxylic acid
  参考文献：
  名称：

  Efficient Assembly of 2,5,6-Substituted Pyrimidines via MgI₂-Mediated Morita−Baylis−Hillman Reaction

  摘要：

  A mild and efficient protocol for the synthesis of a 2,6-disubstituted pyrimidine-5-carboxylate library via a Morita-Baylis-Hillman (MBH) adduct is described. Herein, the three step methodology involves the use of substituted alpha-iodomethylene beta-keto ester intermediates obtained after oxidation of the MBH adducts, which are condensed with various types of amidine or guanidine derivatives, to generate the 2, 6-disubstituted pyrimidines-5-carboxylate libraries.

  DOI：

  10.1021/cc100001e

文献信息

• Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors
  作者：Haiyong Jia、Ji Yu、Xianhong Du、Srinivasulu Cherukupalli、Peng Zhan、Xinyong Liu

  DOI：10.1016/j.ejmech.2020.112495

  日期：2020.9

  The capsid assembly is a significant phase for the hepatitis B virus (HBV) lifespan and is an essential target for anti-HBV drug discovery and development. Herein, we used scaffold hopping, bioisosterism, and pharmacophore hybrid-based strategies to design and synthesize six series of various heterocycle derivatives (pyrazole, thiazole, pyrazine, pyrimidine, and pyridine) and screened for in vitro

  衣壳装配是乙肝病毒（HBV）寿命的重要阶段，也是抗HBV药物发现和开发的重要目标。在本文中，我们使用基于支架跳跃，生物等位基因和药效团杂交的策略设计和合成了六个系列的各种杂环衍生物（吡唑，噻唑，吡嗪，嘧啶和吡啶），并筛选了体外抗HBV非核苷活性。候选药物NZ-4和AT-130用作先导化合物。与先导化合物NZ-4相比，几种化合物具有突出的抗HBV活性，阳性药物拉米夫定，尤其是化合物II-8b，具有最突出的抗HBV DNA复制活性（IC 50 = 2.2±1.1μM）。还化合物IV-8eVII-5b和VII-5b分别显示出最佳的体外抗HBsAg分泌（IC 50 = 3.8±0.7μM，CC 50 > 100μM）和抗HBeAg分泌（IC 50 = 9.7±2.8μM，CC 50 > 100μM）。此外，II-8b可以以良好的亲和常数（K D = 60.0μM）与HBV衣壳蛋白相互作用，这与先导化合物NZ-4（K